The Global Health Body Issues Alert Over Acute Shortage of Weight-Loss Medications
Fewer than one in 10 individuals who could benefit from obesity jabs such as Wegovy can access them, states the WHO as it publishes its initial recommendations on the medications.
Considering more than one billion individuals worldwide now living with obesity, it is urging more widespread and fairer availability to GLP-1 medication.
According to forecasts, over two billion will be obese by 2030 unless action is taken.
"Our latest guidelines affirms that obesity is a long-term condition that can be addressed with thorough and ongoing support," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are key hurdles to universal availability to the treatments that can help people shift considerable body mass, says the agency.
Weight-Loss Drug Scarcity
Even under the current most optimistic outlook, the manufacturing of these medications could only cover around 100 million people – less than 10% of eligible patients, per the health organization.
The recommendation encourages governments and firms to increase access, by strategies including voluntary licensing.
A patent on a key compound – the main ingredient of a leading brand – is due to expire in a number of nations in 2026.
How Weight-Loss Injections Operate
These medications mimick a natural hormone to delay gastric emptying, suppress the appetite and increase the sense of being full so people consume fewer calories.
Individuals typically begin shedding pounds after several weeks of commencing the regular doses.
Evidence indicates users may regain a significant portion within a year of halting the drug, when their usual appetite return.
To be carrying excess weight raises your likelihood for contracting health problems, like type 2 diabetes, cardiovascular issues, brain attack, and some cancers.
Excess weight impacts individuals in all nations and was responsible for millions of deaths worldwide in 2024, per the WHO.
